Teclistamab Plus Darzalex Found to Ease Cancer Burden in Phase 1 Trial
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory…
News
Nexpovio Triple Combo Approved as Myeloma Treatment in Europe
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat…
Tecvayli Recommended for Conditional Approval in Europe
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with…
Pepaxti Combo Favored to Treat Advanced Multiple Myeloma in EU
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer…
List of Rare Diseases Tops 10,000 – and Is Growing – New Analysis Finds
Note: This story was updated July 13, 2022, to correct the name of Rare-X’s CEO Charlene Son Rigby. Nonprofits, scientists, governmental organizations, and…
Talquetamab Named a Breakthrough Therapy for Hard-to-treat Myeloma
Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA)…
1st CAR T-Cell Therapy in China for Myeloma Now Under Review
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell…
Novel Immunotherapy QXL138AM Wins Orphan Drug Status in US
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Nammi Therapeutics’ lead immunotherapy candidate QXL138AM for multiple myeloma. The…
CYT-338 Shows Anticancer Activity in Preclinical Tests
CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer cells, has shown promising anti-cancer…
CAR T-cell Therapy Safe, Effective in Treatment-resistant Myeloma: Study
A CAR T-cell therapy called CART-ddBCMA that targets the protein BCMA — produced at high levels in myeloma cells — safely led to lasting…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment